AAAAAA
Results:
1-14
|
Results: 14
Authors:
TOMITA Y
FUKUI C
KUDO H
KODA J
YABE K
Citation: Y. Tomita et al., COOPERATIVE PROTECTION SYSTEM WITH AN AGENT MODEL, IEEE transactions on power delivery, 13(4), 1998, pp. 1060-1066
Authors:
VINE W
BLASE E
KODA J
YOUNG A
Citation: W. Vine et al., PLASMA AMYLIN CONCENTRATIONS IN FASTED AND FED RATS QUANTIFIED BY A MONOCLONAL IMMUNOENZYMOMETRIC ASSAY, Hormone and Metabolic Research, 30(9), 1998, pp. 581-585
Authors:
FINEMAN M
KODA J
KOLTERMAN O
Citation: M. Fineman et al., SUBCUTANEOUS ADMINISTRATION OF A HUMAN AMYLIN ANALOG SUPPRESSES POSTPRANDIAL PLASMA-GLUCAGON CONCENTRATIONS IN TYPE-1 DIABETIC-PATIENTS, Diabetes, 47, 1998, pp. 346-346
Authors:
THOMPSON RG
GOTTLIEB A
ORGAN K
KODA J
KISICKI J
KOLTERMAN OG
Citation: Rg. Thompson et al., PRAMLINTIDE - A HUMAN AMYLIN ANALOG REDUCED POSTPRANDIAL PLASMA-GLUCOSE, INSULIN, AND C-PEPTIDE CONCENTRATIONS IN PATIENTS WITH TYPE-2 DIABETES, Diabetic medicine, 14(7), 1997, pp. 547-555
Authors:
VINE W
BLASE E
SMITH P
LACHAPPELL R
PERCY A
KODA J
YOUNG A
Citation: W. Vine et al., PLASMA AMYLIN CONCENTRATIONS IN RATS - UTILITY OF A MONOCLONAL IMMUNOENZYMOMETRIC ASSAY, Diabetologia, 40, 1997, pp. 1183-1183
FASTING TOTAL PLASMA AMYLIN CONCENTRATION PREDICTS DETERIORATION IN GLUCOSE-TOLERANCE OVER 4.5 YEARS
Authors:
WAREHAM N
WILLIAMS D
FINEMAN M
KODA J
ANDERSON S
DAY N
HALES CN
Citation: N. Wareham et al., FASTING TOTAL PLASMA AMYLIN CONCENTRATION PREDICTS DETERIORATION IN GLUCOSE-TOLERANCE OVER 4.5 YEARS, Diabetes, 46, 1997, pp. 78-78
Authors:
FINEMAN M
KOLTERMAN O
THOMPSON R
KODA J
Citation: M. Fineman et al., THE HUMAN AMYLIN ANALOG PRAMLINTIDE INHIBITED GLUCAGON-SECRETION IN TYPE-I DIABETIC SUBJECTS, Diabetes, 46, 1997, pp. 117-117
Authors:
YABE K
KODA J
YOSHIDA K
CHIANG KH
KHEDKAR PS
LEONARD DJ
MILLER NW
Citation: K. Yabe et al., CONCEPTUAL DESIGNS OF AI-BASED SYSTEMS FOR LOCAL PREDICTION OF VOLTAGE COLLAPSE, IEEE transactions on power systems, 11(1), 1996, pp. 137-144
Authors:
DIMSDALE JE
KOLTERMAN O
KODA J
NELESEN R
Citation: Je. Dimsdale et al., EFFECT OF RACE AND HYPERTENSION ON PLASMA AMYLIN CONCENTRATIONS, Hypertension, 27(6), 1996, pp. 1273-1276
Authors:
COLBURN WA
GOTTLIEB AB
KODA J
KOLTERMAN OG
Citation: Wa. Colburn et al., PHARMACOKINETICS AND PHARMACODYNAMICS OF AC137 (25,28,29-TRIPRO-AMYLIN, HUMAN) AFTER INTRAVENOUS BOLUS AND INFUSION DOSES IN PATIENTS WITH INSULIN-DEPENDENT DIABETES, Journal of clinical pharmacology, 36(1), 1996, pp. 13-24
Authors:
VINE W
PERCY A
GEDULIN B
MOORE C
SMITH P
CROCKER L
KODA J
YOUNG AA
Citation: W. Vine et al., EVIDENCE FOR METABOLIC ACTION OF ENDOGENOUS AMYLIN FROM EFFECTS OF A NEUTRALIZING MONOCLONAL-ANTIBODY IN RATS, Diabetes, 44, 1995, pp. 251-251
Authors:
RINK TJ
BEAUMONT K
KODA J
YOUNG A
Citation: Tj. Rink et al., STRUCTURE AND BIOLOGY OF AMYLIN, Trends in pharmacological sciences, 14(4), 1993, pp. 113-118
Authors:
KODA J
FINEMAN M
PERCY A
BLASE E
LILLIOJA S
Citation: J. Koda et al., USE OF A NEW 2-SITE IMMUNOASSAY FOR AMYLIN TO CHARACTERIZE AMYLIN HORMONE RESPONSE IN PIMA-INDIANS, Diabetologia, 36, 1993, pp. 10000137-10000137
Authors:
GEDULIN B
LARSON E
PROVOST S
KODA J
Citation: B. Gedulin et al., THE SELECTIVE AMYLIN ANTAGONIST, AC187, ENHANCES THE INSULIN-RESPONSEDURING INTRAVENOUS GLUCOSE-TOLERANCE TESTS IN ANESTHETIZED RATS, Diabetes, 42, 1993, pp. 229-229
Risultati:
1-14
|